Shanghai Henlius Biotech
Latest round
- Series B
Last raised
- Jul 2018
Total raised
- $180M
Investors
- 7
About Shanghai Henlius Biotech
Founded in 2010 and based in Shanghai, China, Shanghai Henlius Biotech, Inc. operates as a biopharmaceutical company that focuses on the research and development of antibody drugs and related products. It was recognized as the National High-tech Enterprise. Jun Zhu, the executive director and chief executive officer of the company, used to serve as the chief executive officer of Jiasheng China and the global vice president of IQVIA. The company's commercial production base and supporting quality management system have received GMP certification in China, the European Union, and the United States. It has 3 production base in Xuhui and Songjiang. The company established a branch office in Shanghai in 2017. In September 2019, the company was listed on the Hong Kong Exchanges and Clearing Limited. Shanghai Henlius Biotech, Inc. mainly engages in the research, development, production, and sales of antibody drugs and related products. The company has conducted over 30 clinical studies for 16 products globally. It has a product pipeline of more than 20 innovative monoclonal antibody and tumor immunology combination therapy candidates, including HLX01, HLX02, HLX06, etc. Products can be used in the treatment of oncology, autoimmune diseases, ophthalmic diseases, and other diseases. The company generates revenue by selling antibody drugs.
Who invested in Shanghai Henlius Biotech
7 investors across 3 rounds
See all investors in Shanghai Henlius Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Shanghai Henlius Biotech
Who invested in Shanghai Henlius Biotech?
Shanghai Henlius Biotech has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Shanghai Henlius Biotech raised?
Shanghai Henlius Biotech has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Shanghai Henlius Biotech last raise money?
Shanghai Henlius Biotech's most recent round on record is a Series B, in Jul 2018.
What does Shanghai Henlius Biotech do?
Founded in 2010 and based in Shanghai, China, Shanghai Henlius Biotech, Inc.
Where is Shanghai Henlius Biotech headquartered?
Shanghai Henlius Biotech is headquartered in Shanghai, China.
Which VCs invest in companies like Shanghai Henlius Biotech?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Shanghai Henlius Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Shanghai Henlius Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.